Place Controlled Study to Treat Recurrent Herpes Labialis.

This study has been completed.
Sponsor:
Collaborator:
Devirex AG
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00914745
First received: June 2, 2009
Last updated: August 5, 2011
Last verified: May 2011
  Purpose

About 80% of the worldwide population is positive on HSV antibodies. In the United States the lifetime prevalence of recurrent herpes labialis is estimated at 20% to 40%, with approximately 100 million episodes occurring in the country every year. In Switzerland about 70% of the adult population is positive on HSV-1 and about 20% is positive on HSV-2.

The Herpes simplex virus has a lipid bilayer (virus-envelope), which causes the sensitiveness, to any kind of detergents. Within this bilayer cholesterol molecules are integrated and play a crucial role in virus entry into host cells. In vitro experiments have clearly shown that the depletion of cholesterol in HSV-envelope with 2- HPßCD has inhibited the ability of the virus to infect host cells.

The aim of this clinical trial is to reduce the number of Herpes labialis relapse and to provide patients with recurrent Herpes labialis a real benefit, concerning the simple mechanism of action and the negligible side effects. Patients having problems in swallowing the antiviral pills of standard treatment, will find with 2- HPßCD a drug, that just has to be applied on the lips, which increases patient's quality of life tremendously.

  • Trial with medicinal product

Condition Intervention Phase
Recurrent Herpes Labialis
Drug: Ointment
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Single Center Phase I/II, Placebo Controlled, Randomized, Double-Blind Study to Treat Recurrent Herpes Labialis by Topical Treatment With Hydroxypropyl-Beta-Cyclodextrin-Ointment (HPßCD-20% Ointment)

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Reducing the number of Herpes labialis relapse. [ Time Frame: June 2009 - Mai 2010 ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: April 2009
Study Completion Date: May 2011
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Ointment
    Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria: Patients will be enrolled in the study if they fulfill the following inclusion criteria:

  1. 18 to 50 years old,
  2. Medical history of Herpes labialis with lesions on the lips or in the perioral area (<1cm from the border of the lips).
  3. At least eight recurrences of labial herpes during the previous year before being en-rolled in the study.
  4. Ability and willingness to participate in the study.
  5. Voluntary written informed consent.

Exclusion criteria: Patients who fulfill any one of the following exclusion criteria may not be enrolled in the study:

  1. Females with child bearing potential who are not using a reliable, medically accepted method of birth control (e.g. surgical, intrauterine contraceptive device, birth control pill, double barrier, hormone delivery systems such as implants or injectables, condoms or diaphragm (each in combination with contraceptive creams, foams, etc.).
  2. Pregnant or breast feeding female, or women planning to become pregnant during the trial.
  3. Medical history of immunosuppression by radiotherapy, chemo therapy, immunomodulatory drugs, or HIV.
  4. Participation in another clinical study within 30 days prior to application of 2-HPßCD.
  5. Medical history of any severe diseases like hepatitis, renal or liver dysfunction, cardiovascular, gastrointestinal, malignant tumor(s), or psychiatric disorders etc., which might influence the assessments or conduct of the trial by the discretion of the investigator.
  6. Intake or application of antivirals or other prohibited concomitant medication within 30 days prior to application of 2-HPßCD, or plan to take such drugs during the trial.
  7. Use of anti-inflammatory medications and steroids during the course of the study.
  8. Eczema herpeticatum or any history of other skin disease that would predispose to ec-zema herpeticatum.
  9. Any abnormal perioral skin condition.
  10. Known or suspected allergic or adverse response to the investigational product (2- HPßCD) or its excipients (PEG 400, and PEG 8000).
  11. Inability to follow the study protocol.
  12. Medical history of alcohol and/ or drug abuse within the previous 12 months before enrollment in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00914745

Locations
Switzerland
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Devirex AG
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: Thomas Kuendig, University Zurich
ClinicalTrials.gov Identifier: NCT00914745     History of Changes
Other Study ID Numbers: ZU-HPB-001
Study First Received: June 2, 2009
Last Updated: August 5, 2011
Health Authority: Switzerland: Federal Office of Public Health

Additional relevant MeSH terms:
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases

ClinicalTrials.gov processed this record on July 24, 2014